It has previously been shown that rats trained 5 hr after intracerebral injection of acetoxycycloheximide show a transient amnesia at 24 hr after training. We have tested the possibility that adrenergic stimulants might provide protection from the amnesia. Metaraminol, given either before or after training or before testing, prevents the drug-induced amnesia. D-Amphetamine, injected soon after training, also prevents the amnesia. A model is presented to explain the drug-induced amnesia in terms of both the assumed effect of acetoxycycloheximide on the adrenergic system and prevention of the amnesia by metaraminol and D-amphetamine.
The protein synthesis inhibitors, puromycin and acetoxycycloheximide (AXM), have been used in a number of experiments designed to determine whether protein synthesis is necessary for the formation of a long-term memory (1, 2) . Although puromycin does indeed act to produce a reliable and long-lasting amnesia, it has become clear that the amnesia can be attributed to factors other than the temporary cessation of protein synthesis. Thus, a mixture of puromycin and AXM, which produces a more profound inhibition of protein synthesis than puromycin alone, has no amnesic effect (3) .
Furthermore, the puromycin-induced amnesia can be reversed by various treatments, including the injection of drugs acting on the adrenergic system. It appears that the puromycin-induced amnesia may be the result of puromycinpeptides that block norepinephrine receptor sites at synapses (4) . This hypothesis is in accord with the apparent need for adequate concentrations of norepinephrine both at the time of testing (5) and at the time of consolidation immediately after training (6) .
Various amnesic effects of AXM (or cycloheximide) have been reported. Barondes and Cohen have found a long-lasting amnesia that is induced in minimally trained mice when AXM or cycloheximide is injected before or immediately after training (7) . A transient amnesia has been observed in mice both by Flexner and Flexner (8) and by Quartermain et at. (9) . Rats trained 5 hrs after intracerebral injections of AXM develop a transient amnesia at 24 hrs after training (10) .
Possibly AXM, like puromycin, has effects on the norepinephrine system that are responsible for the amnesic effects of the drug. If this were the case, adrenergic simulants might provide protection from amnesia. We have found that the temporary amnesia induced in rats by injection of AXM is prevented by an injection of metaraminol given either before or after training or before testing. D-Amphetamine injected soon after training also prevents the AXM-induced amnesia. These results with D-amphetamine are similar to those reported by Barondes and Cohen (11 The first group of experiments was done to test the reproducibility of the previously described transient amnesia that followed training in the presence of AXM. In the second group, metaraminol was injected 0.5 hr before training to evaluate its effect on the memory of rats that had been injected intracerebrally with saline. The remaining three groups all consisted of AXM-treated rats; in the first, metaraminol was injected 0.5 hr before training; in the second, metaraminol was given for up to 23.5 hr after training; in the final group, D-amphetamine was administered within 2 hr after training.
RESULTS
After treatment with metaraminol, rats were slightly lethargic in their cages but performed normally in the maze. There was no significant difference (Students' t-test; P > 0.1) in the number of trails to reach criterion on initial training between these rats and those that were not treated with metaraminol (mean ± SE = 15.8 ± 4.2 and 15.6 ± 2.6, respectively).
By contrast, D-amphetamine caused marked behavioral excitation, which lasted 1-2 hr and seriously affected maze performance; its use was limited to a relatively short interval after training. 5 hr before training and tested either 24 hr or 6 days after training showed, respectively, loss and retention of memory (Groups la and lb). The difference between the scores of these two subgroups is highly significant (P < 0.001), in agreement with reported results (10) . Rats injected intracerebrally with saline 5 hr before training and with metaraminol 0.5 hr before training had a high level of retention of memory at 24 hr (Group 2) that was not significantly different (P > 0.1) from that of an untreated control group studied previously (10) .
Group 3 received AXM 5 hr before training. Group 3b, given metaraminol 0.5 hr before training, had significantly greater retention 24 hr after training (P > 0.01) than its control injected with saline (Group 3a).
Group 4 (treated with AXM 5 hr before training) received metaraminol at various times between training and testing. The controls for this group, in which saline was injected 0.5 hr before testing, had a low level of retention when tested at 24 hr (Group 4a). By contrast, rats that received metaraminol up to 2 hr after training (Group 4b) had significantly greater retention (P < 0.01) as did those treated with metaraminol 0.5-2 hr before testing (P < 0.001). Metaraminol was without significant effect on savings when administered 2.5-21. 5 Numbers above the arrows refer to time intervals in hours. AXM = acetoxycycloheximide; MA = metaraminol; AMP = D-amphetamine; (IP) = intraperitoneal. Buffalo rats were used in Groups la, lb, and 2; Fisher rats were used in the remaining groups.
earlier view based on assumed roles in memory of messenger RNA and protein.
The possibility has been considered that motivation or other factors present at the time of training or of retention-testing (and not part of the momory process itself) might account for the results. These less-specific factors seem to be ruled out by the finding that metaraminol and D-amphetamine given up to 2 hr after training protect memory and, additionally, that this protection is lost when the injection of metaraminol is delayed beyond 2 hr after training and up to 2 hr before testing.
The following model seems sufficient to account for our results: (a) norepinephrine released during the time of training and consolidation leads to facilitatory changes in the specific network of synapses that are associated with the training situation; (b) norepinephrine released at the time of testing causes preferential reactivation of this previously facilitated network; (c) injection of AXM leads to a fall in the amount of norepinephrine released and to a correlative fall in the degree of facilitation; (d) at 24 hr, norepinephrine is still not available in sufficient quantities to reactivate the network, resulting in a "failure of expression of memory"; (e) at 6 days, the norepinephrine system has recovered and the memory is expressed.
According to the above model amphetamine and metaraminol could prevent amnesia as follows: (a) When they are given within 2 hr of training, adequate facilitation would occur and the quantity of norepinephrine available at the time of testing would be sufficient to reactivate the fully facilitated network. (b) When they are given within 2 hr of testing, the quantity of norepinephrine would be greater during the test and sufficient to reactivate even the partly facilitated network. (c) When they are given between these critical periods, the transient elevation of the available norepinephrine concentration would have no effect.
This model requires an undefined process referred to as "facilitation," which occurs during the training and consolidation period.
